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Abstract 
The term “acquired hepatocerebral degeneration” (AHD) was coined to describe 
clinical entity distinct from genetically defined Wilson’s disease. AHD is chronic 
neurological disorder, characterized by extrapyramidal and neuropsychiatric symptoms 
accompanied with advanced liver disease with portosystemic shunts. In majority of AHD 
cases, extrapyramidal symptoms appear in the presence of known liver disease. Here we 
present a patient with subacute onset of bilateral, asymmetric, hypokinetic-rigid syndrome and 
ataxia as initial presentation of liver cirrhosis. Manganese toxicity have major role in AHD 
pathogenesis. Failure of liver detoxification and presence of portosystemic shunting enables 
neurotoxic substance of manganese to avoid hepatic metabolism and to enter and accumulate 
in central nervous system. Predilection brain regions for manganese deposits are globus 
pallidum (GP) and substantia nigra (SN). Characteristic MRI findings of bilateral, 
symmetrical hyperintensities of GP and SN on T1-weighted sequences supported the 
diagnosis of AHD in our patient. In addition, increased T2 signal in dendate nuclei seen in our 
patient is rare radiological finding. So far, no consensus guidelines regarding medical 
treatment of AHD exist. We initiated low-dose levodopa treatment, but failed to provide 
beneficial effect. In conclusion, AHD is distinct clinical entity that should be included in 
differential diagnosis of both typical and atypical parkinsonian syndromes. Furthermore, our 
case highlights the importance of performing MRI in patients with atypical parkinsonism. 
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Parkinsonian Syndrome and Ataxia as a Presenting Finding of  
Acquired Hepatocerebral Degeneration 
 
Introduction:  
Connection between liver diseases and central nervous system (CNS) impairment has 
been well established. One century after description of neurological dysfunction associated 
with cirrhosis unrelated to Wilson’s disease (van Woerkom 1914), relationship between brain 
disorders and abnormal liver function still intrigues the scientific community. In 1965, the 
term “acquired hepatocerebral degeneration” (AHD) was coined to describe clinical entity 
distinct from genetically defined Wilson’s disease (Victor et al. 1965). AHD is chronic 
neurological disorder characterized by extrapyramidal and neuropsychiatric symptoms 
accompanied with advanced liver disease with portosystemic shunts (Ferrara and Jankovic 
2009; Butterworth 2012). Multifarious clinical manifestation of AHD includes cognitive 
decline, apathy, somnolence, ataxia, myelopathy, dysarthria, and wide variety of abnormal 
movements such as parkinsonism, dystonia, cranial dyskinesias and chorea. Having diverse 
clinical manifestation AHD may mimic a broad range of disease. Here we present a patient 
with parkinsonian syndrome and ataxia as initial presentation of liver cirrhosis.  
Case presentation:  
A 57-year-old female was hospitalized at movement disorders unit for evaluation of 
subacute onset, hypokinetic-rigid syndrome. Patient described having stiffness and pain in her 
shoulders and sense of generalized slowness. She also noticed her left arm being “clumsy”. 
Her symptoms started gradually during ten months prior to hospital admission. Patient’s 
husband revealed that his wife experienced several episodes of disorientation and impaired 
concentration with spontaneous resolution within 24 hours. Her past medical history included 
cholecystectomy, hysterectomy and adnexectomy due to myoma and ovarian cysts. There was 
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no prior history of parkinsonism, carbon monoxide poisoning, CNS infection, neuroleptic and 
toxin exposure. She denied the presence of any neurological diseases in her family, but 
confessed daily consumption of 200 – 500 ml of red wine. She was not taking any medical 
therapy on admission. On initial examination she was alert an orientated, scoring 27/30 on 
Mini Mental State Examination mostly due to impaired attention. Her voice was mildly 
hypophonic and she had reduced facial expression. Bilateral asymmetric rigidity and 
bradykinesia, more severe on her left extremities were present. Low-amplitude postural 
tremor was observed. She walked on wide base with short steps and had reduced left arm 
swing. Balance impairment on retropulsion test was present. Deep tendon reflexes were 
symmetric and none of the pathologic reflexes were inducted. Laboratory examination 
revealed thrombocytopenia (77,000 platelets/dl), abnormal coagulation profile with 
prothrombin activity 62%, abnormal liver function tests (AST 45 IU/L; GGT 88 IU/L; total 
bilirubin 49 mg/dl; direct bilirubin 14 mg/dl), total protein 59 g/L, albumin 31 g/L and high 
ammonia level of 143 µmol/L. Red and white blood cell count, erythrocyte sedimentation 
rate, electrolyte panel, urea, creatinine, alkaline phosphatase, albumin/globulin ratio, IgG, 
IgA, IgM, thyroid function tests, vitamin B12 and folic acid levels were all within the normal 
range. Abdominal ultrasound revealed features consistent with cirrhosis including dilatation 
of coronary vein. Normal concentration of ceruloplasmin, serum and urine copper and 
absence of Kayser-Fleischer ring excluded Wilson's disease. Tumour markers (AFP, CEA, 
CA 125, CA 19-9), antinuclear antibody, antimitochondrial antibody and liver-kidney 
microsomal antibody levels were normal. Serological testing for hepatitis A, hepatitis B and 
hepatitis C was negative. Magnetic resonance imaging (MRI) of the brain was performed and 
showed diffuse brain atrophy, symmetrically increased signal in substantia nigra (SN) and 
globus pallidum (GP) on T1-weighted sequences (Fig. 1), and increased T2 signal within both 
dentate nucleus (Fig. 2). According to clinical and radiological data, we made the diagnosis of 
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alcoholic liver cirrhosis grade B9 of the Child Pugh classification, with parkinsonian 
syndrome and mild encephalopathy as neurological complications in spectrum of AHD 
condition. Short-term, low-dose levodopa treatment was tried, but failed to provide beneficial 
effect. We have referred our patient to gastroenterologist for further diagnostic procedures and 
treatment.  
Discussion: 
Liver diseases may cause a variety of neurological impairment, with hepatic 
encephalopathy being most common. The prevalence of AHD among patients with cirrhosis 
varies between 1-21% (Butterworth 2012; Burkhard et al. 2003). In contrast to acute onset 
and treatment responsive hepatic encephalopathy, AHD represents chronic disorder, highly 
resistant to treatment. AHD – related parkinsonism is characterized by rapid progression, 
bilateral and mostly symmetrical bradykinesia, rigidity, action and postural tremor, postural 
instability and shuffling gait. However, mild side predominance like in our patient can be seen 
(Burkhard et al. 2003). In majority of AHD cases published so far, extrapyramidal symptoms 
usually appear in presence of known liver disease. There are only few reports similar to ours 
that presented patient with parkinsonian syndrome and ataxia as initial manifestation of the 
occult cirrhosis (Noone et al. 2008). 
Manganese toxicity have major role in AHD genesis, although impact of ammonia and 
aromatic amino acid should not be disregarded. More recently, mutation in SLC30A10 (Solute 
Carrier Family 30, Member 10) gene, encoding a manganese transporter was discovered as a 
cause of inherited, inborn error of manganese metabolism (Tuschl et al. 2012). This 
autosomal recessive condition has similar phenotypical manifestation as AHD, but onset of 
symptoms is usually in childhood compared to AHD. Several investigations demonstrated 
increased manganese levels in blood, cerebrospinal fluid and brain tissue in patient with liver 
cirrhosis (Burkhard et al. 2003; Pomier-Layrargues et al. 1995). Failure of liver detoxification 
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and presence of portosystemic shunting enables neurotoxic substance of manganese to avoid 
hepatic metabolism and to enter and accumulate in CNS. Predilection brain regions for 
manganese deposits are GP and SN. Characteristic MRI findings include bilateral, 
symmetrical hyperintensities of GP on T1-weighted sequences with normal finding on T2-
weighted sequences (Fernández-Rodriguez et al. 2010). Increased T2 signal in dendate nuclei 
seen in our patient is rare radiological finding and has rarely been reported (Park and Heo 
2004). Although exact mechanism of manganese induced movement abnormalities is still 
unknown, nuclear medicine tomography imaging technique studies point to nigrostriatal 
dopamine system dysfunction as a possible cause (Guilarte et al. 2006). There is paucity of 
published data regarding medical treatment of AHD and no consensus guidelines exist. 
Levodopa replacement therapy can provide amelioration of symptoms in some cases 
(Butterworth 2012). There was a report of significant improvement of parkinsonism with 
decrease of high signal intensities in GP on follow-up MRI, in patient treated with chelate 
agent trientine (Park et al. 2008). Marked alleviation and complete reversal of symptoms was 
observed following liver transplantation (Stracciari et al. 2001), although post-surgical 
residual extrapyramidal symptoms have been reported as well (Shulman et al. 2003). Less 
invasive, endovascular occlusion of portal-systemic shunts, was shown to provide beneficial 
effect in patient with AHD, but relief was temporary (Condat et al. 1999).  
In conclusion, AHD is distinct clinical entity that should be included in differential 
diagnosis of both typical and atypical parkinsonian syndromes. Having in mind diversity in 
clinical presentation AHD is frequently overlooked condition and putting correct diagnosis 
remains clinical challenge.  
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Fig. 1 Symmetrically increased signal in globus pallidum on T1-weighted sequences 
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Fig. 2 Symmetrically increased signal in dentate nuclei on T2-weighted sequences 
 
 
 
